Drug Profile
Epicatechin - Epirium Bio
Alternative Names: (+)- Epicatechin; EB-002; EPM-01Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Cardero Therapeutics
- Developer Epirium Bio; Mayo Clinic; University of California, Davis
- Class Antibacterials; Benzopyrans; Catechols; Heart failure therapies; Small molecules
- Mechanism of Action Mitochondrial protein modulators; Oxidoreductase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Friedreich's ataxia
- No development reported Duchenne muscular dystrophy; Heart failure; Mitochondrial disorders
Most Recent Events
- 01 Mar 2022 Epiruim Bio completes a phase I trial in Duchenne muscular dystrophy (In adolescents, In adults) in USA (PO) (NCT04386304)
- 30 Sep 2020 No development reported - Phase-I/II for Duchenne muscular dystrophy (In adolescents, In children) in USA (PO)
- 30 Sep 2020 No development reported - Phase-II for Duchenne muscular dystrophy (In adults) in USA (PO)